Entinostat May Add Benefit to High-Dose IL-2 in RCC

Article

The combination of the novel histone deacetylase inhibitor entinostat and high-dose interleukin-2 yielded a promising response rate in patients with metastatic renal cell carcinoma.

The combination of the novel histone deacetylase (HDAC) inhibitor entinostat and high-dose interleukin-2 (IL-2) yielded a promising response rate in patients with metastatic renal cell carcinoma (RCC), according to a phase II trial. Results were presented at the 2016 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, held January 7–9 in San Francisco (abstract 500).

High-dose IL-2 is approved for certain patients with metastatic RCC, with a collection of earlier trials showing an objective response rate of 15%, with some indicating higher rates. Preclinical studies have found a potentially synergistic effect of high-dose IL-2 and entinostat; the latter down-regulates FOXP3 expression in regulatory T cells (Tregs).

“Our hypothesis has been that the inhibitory effect of entinostat on Tregs may increase the response rate and progression-free survival in patients receiving high-dose IL-2,” said lead author Roberto Pili, MD, of Indiana University in Indianapolis.

In this trial, 47 patients were included, with a median age of 58 years. All had prior nephrectomy and an ECOG performance status of 0, and none had prior first-line systemic therapy. The metastatic sites included lungs (36%), lymph nodes (26%), bones (7%), and liver (6%).

At the time of the presentation, 40% of the patients were still receiving treatment; 37 patients were evaluable for response. The objective response rate was 35% (13 patients); 3 of those were complete responses and 10 were partial responses.

The median progression-free survival was 16.1 months, and the 3-year progression-free survival rate was 16%. The median progression-free survival among responders was 28.5 months, compared with 5.7 months in those who did not experience a response.

The most common grade 3 or higher adverse event was hypophosphatemia in 16.4%, followed by decreased lymphocytes (15.1%), hypocalcemia (7.2%), and others.

“These results suggest that the selective class I HDAC inhibitor entinostat may indeed increase the antitumor effect of high-dose IL-2 by modulating immunosuppressive cells,” Pili concluded.

The discussant for the session, Neeraj Agarwal, MD, of the Huntsman Cancer Institute at the University of Utah in Salt Lake City, noted that the response rate in this trial is the highest ever reported with high-dose IL-2 therapy. “However, the small sample size of the study means that it is at best hypothesis generating, and these results need to be evaluated in a large clinical trial,” he said. He added that stable disease, which was not reported in this trial of entinostat, should be included in future trials since it may represent meaningful clinical benefit.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Related Content